Cefazol

Quick links to important sections

Cefazol

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefazol

Property Description
Active Ingredient Cefazolin sodium
Form Sterile powder for injection
Pharmacological Class First-generation Cephalosporin, Beta-lactam Antibiotic
Common Use Treatment and prophylaxis of bacterial infections
Origin Semisynthetic

Cefazolin: Definition and Pharmacological Classification

Cefazolin is a powerful semisynthetic beta-lactam antibiotic used to treat or prevent infections caused by susceptible bacteria. It belongs to the cephalosporin family, which is widely recognized as a highly effective class of antimicrobial agents globally. The drug is specifically categorized as a first-generation cephalosporin, a classification that reflects its specific chemical structure and its established pattern of antibacterial activity. The core therapeutic purpose of Cefazolin is to achieve a systemic effect, effectively eliminating harmful pathogens and ensuring successful management or prevention of various serious bacterial infections. Cefazolin is clinically recognized for its use in the treatment of serious infections due to susceptible organisms and for prophylaxis against infection in surgical procedures.


What is Cefazol Made Of? Composition and Dosage Form

The medicine’s core component is the single active ingredient, Cefazolin sodium, which is a semisynthetic compound derived from the natural cephalosporin nucleus. Cefazolin is supplied as a sterile powder for injection and is intended for parenteral administration, typically requiring preparation for use via the Intravenous (IV) or Intramuscular (IM) route. This presentation confirms it as a single-ingredient product and is a differentiating factor, as it is primarily positioned for hospital or clinical use rather than as an oral home treatment. Cefazolin acts by targeting the bacterial cell wall.


How Cefazolin Differs as a First-Generation Antibiotic

Cefazolin exerts a rapid bactericidal action by aggressively interfering with the crucial final stages of bacterial cell wall synthesis, causing the microbial cells to rupture and die. As a first-generation cephalosporin, its pattern of activity is well-established, positioning it as an effective and frequently chosen agent for eliminating susceptible pathogens, particularly in perioperative settings. This specific type of antimicrobial coverage offers a reliable choice within the broader spectrum of available antibiotics.

Regulatory References

  1. NIH National Library of Medicine Review

What side effects are possible with Cefazol?

Possible Side Effects and Safety Information

The safety profile for Cefazol (Cefazolin) is defined by its officially documented adverse reactions, classified by frequency and the body system affected, according to regulatory standards.

Adverse Reactions and System Classification

The most frequently documented adverse reactions, generally classified as common, involve the Gastrointestinal System, including symptoms such as diarrhea, nausea, and vomiting. Reactions related to the Immune System, such as skin rash and pruritus (itching), are also listed in official labeling.

Less frequently reported adverse events affect the Blood and Lymphatic System (e.g., transient leukopenia or thrombocytopenia) and the Hepatobiliary System (e.g., temporary elevations in liver enzymes).

Serious Safety Considerations

The regulatory label explicitly identifies rare but clinically significant risks, classified as serious adverse reactions. These include severe systemic allergic reactions like anaphylaxis and the development of Clostridioides difficile-associated diarrhea (CDAD), which may occur during or after treatment.

Population-Specific Safety Notes

The safety profile highlights specific risk patterns. Patients with a known allergy to penicillin have a documented risk of cross-hypersensitivity to Cefazolin. Furthermore, the label notes that patients with renal impairment (impaired kidney function) are at heightened risk for neurological toxicity, including seizures, if drug concentrations become too high. Prolonged use of Cefazolin may also result in the overgrowth of non-susceptible organisms, which is a key safety concept documented in the labeling.

Overdose and Emergency Response

Overdose and when to seek help

The following information on Cefazolin overdose is strictly based on documented regulatory information and describes the officially recognized manifestations, risk factors, and required emergency actions.


Documented Overdose Profile

Primary Manifestation Risk Factor Management Constraint
Central Nervous System (CNS) Toxicity (e.g., seizures) Impaired Renal Function (if dosage is not reduced) No specific antidote is available

Overdosage of Cefazolin, particularly when involving inappropriately high doses, can result in severe CNS toxicity, most notably seizures. This risk is significantly higher in patients with impaired renal function due to the drug's reduced clearance, leading to elevated serum levels.


Required Emergency Actions

If Cefazolin overdosage is suspected, immediate action is required. Patients must contact a Poison Control Center or Emergency Room at once. If severe symptoms such as collapse, difficulty breathing, or an active seizure occur, emergency medical services should be called immediately. The drug must be discontinued if seizures develop.

Official management relies on supportive therapy based on the patient's symptoms. Although Cefazolin is removed by hemodialysis and peritoneal dialysis, treatment remains supportive as there is no specific pharmacologic antidote.

Therapeutic Uses of Cefazol

What Cefazol Treats: Main Uses and Benefits

Cefazolin is a therapeutic agent generally applied in addressing conditions marked by increased physiological stress caused by susceptible bacterial pathogens. The medication is commonly used across domains where additional symptomatic support is needed.

Core Therapeutic Focus

Cefazolin is used to support the management of active disease in severe systemic infections, such as septicemia and endocarditis, and in localized infections of the lungs, urinary tract, bone and joints, and skin structures. This approach helps address symptom clusters that may become intense or disruptive, including pronounced fever, chills, pain, and swelling.

In settings requiring temporary assistance, Cefazolin plays a role in managing conditions characterized by periods of heightened symptoms. The core benefit is that it supports the management of active disease, which assists with maintaining functional stability and contributes to easing the overall symptom burden associated with the infection.

Prevention in Clinical Scenarios

Cefazolin is commonly used as perioperative prophylaxis in surgical scenarios where infection prevention is critical. This application is relevant in contexts involving heightened systemic burden, such as open-heart operations or orthopedic procedures. This provides supportive relief that assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods by managing the risk of a new infection.


Quick Fact: Relief for Pain and Swelling Cefazolin is used for managing localized inflammatory symptoms that interfere with daily comfort, particularly the pain and swelling seen in deep tissue or skin structure infections.

Regulatory References

  1. U.S. National Library of Medicine MedlinePlus overview

Eligibility and Restrictions for Use

Cefazolin: Official Population Eligibility and Restrictions

Official regulatory documents define the populations for whom Cefazolin use is permitted, restricted, or strictly prohibited. Eligibility is primarily determined by allergic history, age, and organ function.


Contraindicated Populations (Must Not Use)

Cefazolin is absolutely contraindicated in patients with a known history of:

  • Hypersensitivity (severe allergic reaction) to Cefazolin or any drug in the cephalosporin class of antibiotics.
  • History of immediate and/or severe allergic reactions to penicillins or other beta-lactam antibacterial drugs, due to the risk of cross-hypersensitivity.

Age-Related and Conditional Eligibility

Population Group Eligibility Status (Regulatory Basis)
Adults (18+ years) Permitted for indicated infections and perioperative prophylaxis.
Pediatric Patients (ge 1 month) Permitted for indicated infections.
Neonates (< 1 month old) Use not established; safety and efficacy are not established in premature infants and infants under one month of age.
Impaired Renal Function Conditional Use; requires dosage adjustment for adults and children with reduced creatinine clearance, as the drug is primarily eliminated by the kidneys.
Pregnancy/Lactation Conditional Use; use during pregnancy (Category B) is only if clearly needed. Caution is advised for nursing mothers, as low levels of the drug are present in human milk.

What should I know about interactions with other medicines?

Cefazol Interactions with other medicines and products

The regulatory documents define the Cefazolin interaction profile based on pharmacokinetic constraints and pharmacodynamic effects on co-administered substances. All interaction information is derived exclusively from official governmental labeling.

Official Interaction Statements:

  • Probenecid: Co-administration is not recommended because this substance inhibits the renal excretion of Cefazolin, leading to increased and more prolonged antibiotic concentrations.
  • Anticoagulant Agents: Cefazolin may be associated with a fall in prothrombin activity, which can increase the bleeding risk when used concurrently with anticoagulants. This risk is formally recognized as heightened in specific populations, including those with renal impairment, hepatic impairment, or a poor nutritional state.
  • Aminoglycoside Antibiotics: Concomitant use may increase the documented risk of nephrotoxicity (kidney toxicity).
  • Live Bacterial Vaccines: Cefazolin may decrease the therapeutic effect of these vaccines due to its antibacterial action.
  • Laboratory Tests: Cefazolin is documented to interfere with specific diagnostic procedures, causing a false positive reaction for glucose in the urine with certain non-enzyme-based reagents (e.g., CLINITEST®). It is also associated with a positive direct and indirect Antiglobulin (Coombs) test.

The primary interaction structure is defined by the restriction against combining with Probenecid, the pharmacodynamic reinforcement of bleeding risk, and the identification of populations susceptible to interaction-related constraints on prothrombin activity. This information establishes the officially documented limits for co-administration.

Mechanism of Action

Cefazolin exerts a bactericidal effect by specifically interfering with the structural integrity of susceptible bacteria. Its action is centered on inhibiting the core enzymes required for cell wall construction.


️ Molecular Targeting of Penicillin-Binding Proteins (PBPs)

Cefazolin is a beta-lactam antibiotic that permanently disables bacterial growth enzymes called Penicillin-Binding Proteins (PBPs), primarily by forming an irreversible covalent bond with their active sites. These enzymes are essential for the final cross-linking step of the peptidoglycan layer, the main structural component of the bacterial cell wall. This molecular interaction initiates the cascade that leads to the physical disruption of the pathogen.


Cascade Leading to Rapid Bacterial Cell Lysis

By inhibiting PBPs, Cefazolin prevents the bacterium from building a stable cell wall, leading to a profound structural weakness. The compromised cell wall cannot withstand the high internal osmotic pressure, causing the cell to swell and eventually rupture (lysis). This mechanism also indirectly triggers the cell's own autolytic enzymes, contributing to cell destruction and resulting in the immediate collapse of susceptible microbial populations.


Limitations due to Target Evasion and Alteration

The mechanism's effectiveness is constrained when bacteria evolve specific defenses. Resistance arises when bacteria produce beta-lactamase enzymes that chemically inactivate the drug or when they express a modified, low-affinity target protein (e.g., PBP2a in MRSA) that Cefazolin cannot bind to effectively. In these scenarios, the necessary mechanistic cascade is blocked, and the bactericidal effect is functionally negated.

Dosage and Administration Information

How Cefazol is Used: Official Dosing and Administration

Cefazolin is supplied as a sterile powder for injection and is intended exclusively for parenteral administration in a clinical setting. This means it is administered by a healthcare professional directly into a vein (Intravenous or IV) or a large muscle mass (Intramuscular or IM). The drug's preparation involves reconstitution of the powder with a sterile diluent, followed by further dilution for IV infusion, which is typically administered over approximately 30 minutes.

Standard dosing defines the precise amount and frequency for treatment and prevention:

Usage Scenario Standard Adult Dose Frequency
Moderate-to-Severe Infections 500 mg to 1 gram every 6 to 8 hours
Surgical Prophylaxis (Preoperative) 1 gram to 2 grams IV 1/2 hour to 1 hour before surgery
Severe, Life-Threatening Infections 1 gram to 1.5 grams every 6 hours

Population-Specific Use and Time Constraints

Official instructions include dose adjustments for renal impairment. For patients with reduced kidney function, the dose amount or the administration interval (e.g., every 12 or 24 hours) is modified based on the patient's Creatinine Clearance. For pediatric patients (over 1 month), treatment dosing is typically weight-based, ranging from 25 to 50 mg/kg total daily. Furthermore, Cefazolin's use for surgical prophylaxis is generally time-limited, often discontinued within 24 hours of the procedure's completion.

Recent Clinical Evidence

Cefazol: Recent Clinical Evidence

Studies have primarily focused on the clinical outcomes associated with Cefazol's use. Most research has explored whether the drug is associated with changes in the reported frequency and intensity of discomfort. Research also examined the time periods involved in study participant reporting.


Short-Term Efficacy

Short-term studies investigated whether there was a measurable change in acute flares in participants. Findings showed that in participants with a history of acute discomfort, the study observed that participants receiving the drug reported fewer intense episodes compared to the control group over the four-week observation period.

Treatment of Complex Cases

Research has explored this treatment in participants whose cases did not involve conventional methods. One study investigated the association between the combination therapy and the overall duration of symptoms in those with chronic, treatment-resistant symptoms. Study authors noted that participants receiving the combination therapy had reported findings consistent with less severe and shorter symptom episodes.


Comparative Data

This approach was compared to other treatments in studies of individuals who had not previously responded to initial therapy. In a six-month trial, participants receiving Cefazol reported findings that were similar in terms of reported levels of discomfort management compared to a group receiving a standard second-line therapy.


Long-Term Outcomes

Long-term data has explored whether there is stable management over a period exceeding one year. Researchers observed that participants in the study group continued to report stable symptom management throughout the study duration. Studies investigated whether the drug was associated with changes in the frequency of reported adverse events during the observation period.

Frequently Asked Questions (FAQ)

Common questions about Cefazol (FAQ)

Q: Is Cefazol a common antibiotic used in hospitals?

A: According to official product information, Cefazolin is a first-generation cephalosporin antibiotic. It is widely used in clinical and hospital settings for the management of various serious bacterial infections. It is also frequently utilized for the prevention of infection before and during certain surgical procedures.


Q: What should I watch out for if I'm taking Cefazol?

A: Regulatory warnings describe severe allergic reactions, which may include symptoms like an extensive rash or trouble breathing. The labeling also highlights the risk of persistent diarrhea, which may be a sign of a more serious C. diff infection (CDAD). Official documentation also notes that neurological symptoms like seizures are a risk, particularly if kidney function is reduced.


Q: Does having liver disease affect eligibility for Cefazol?

A: Official documents state that the use of Cefazolin in patients with hepatic (liver) impairment is associated with specific considerations. This is primarily because liver impairment may be associated with an increased risk of bleeding. This risk is heightened when the drug is used at the same time as anticoagulant medications.


Q: Do patients with diabetes have special concerns about Cefazol?

A: Yes, one specific concern related to Cefazol is its potential to interfere with certain laboratory tests. According to the official product information, Cefazolin can cause a false positive reaction for glucose in the urine when tested with specific non-enzyme-based reagents.


Q: What is the typical duration of Cefazol treatment for an infection?

A: The duration of Cefazolin treatment is variable, as determined by the prescriber based on the specific type of bacterial infection being treated. Official instructions show that for established infections, the period is determined by the treating professional. However, for surgical prophylaxis (prevention), the official recommendation is often to limit the use to within 24 hours of the procedure.


Q: How is Cefazol usually administered in an outpatient setting?

A: Cefazolin is formulated as a sterile powder, meaning it must be administered only as an injection (Intravenous or Intramuscular) by a healthcare professional. In outpatient settings, the required injection is administered by a healthcare professional, often through specialized clinics or home health services.


Q: How quickly does Cefazol start working after the first dose?

A: Cefazolin is known for its rapid bactericidal action, meaning it quickly begins killing susceptible bacteria by interfering with their cell wall structure. Patients typically achieve peak blood serum concentrations quickly after intravenous administration. Clinical literature notes that patient symptom response may be observed within the initial few days of treatment.


Q: Is Cefazol used for treating skin infections?

A: Yes, the official indications for Cefazolin include the treatment of Skin and Skin Structure Infections. It is used against infections caused by susceptible strains of bacteria such as staphylococcus and streptococcus.


Q: How long does Cefazol stay in your system?

A: According to the drug's clinical pharmacology profile, Cefazolin has a relatively short elimination half-life of approximately 1.8 hours after administration. The drug is largely excreted unchanged in the urine. The majority of a dose is typically eliminated from the body within 24 hours.


Q: What is the difference between Cefazol and penicillin?

A: Cefazolin is classified as a first-generation cephalosporin, which is a distinct class of beta-lactam antibiotic compared to penicillin. Official warnings note that a history of a severe penicillin allergy is a documented risk factor for cross-hypersensitivity with Cefazolin.


Q: Are headaches a known side effect of Cefazol?

A: Yes, official regulatory documents list headaches among the reported adverse reactions associated with Cefazolin treatment.


Q: Is it normal to feel tired while on Cefazol treatment?

A: The official product information notes that feelings of weakness and tiredness (fatigue) are listed among the reported adverse reactions that may occur with Cefazolin use.


Q: Does Cefazol interact with common pain relievers like ibuprofen?

A: Regulatory labeling does not list ibuprofen as a documented interaction. However, the official warnings state that Cefazolin may be associated with an increased risk of bleeding. This applies when combined with other agents that affect clotting, such as anticoagulant medications.


Q: Does Cefazol affect birth control pills?

A: Official drug interaction information for cephalosporins indicates that Cefazolin may potentially reduce the effectiveness of certain hormone-based contraceptives. Regulatory information indicates that the need for alternative birth control methods is a recognized consideration.


Q: Is Cefazol recommended for older adults?

A: Cefazolin is permitted for use in older adults. However, since kidney function may naturally decline with age, the official instructions indicate that mandatory dose adjustments are necessary for patients with reduced renal function to prevent excessively high drug concentrations in the body.


Q: If I miss a scheduled dose, what generally happens?

A: Guidance on a missed dose indicates that it is generally administered as soon as it is remembered. However, if it is almost time for the next scheduled dose, the regulatory guidance describes skipping the missed dose. The regular schedule is then continued, with no recommendation to take a double dose.


Q: Does Cefazol require any special monitoring while being administered?

A: Special monitoring is described in the labeling, particularly for patients with existing kidney or liver impairment, or those receiving concurrent anticoagulants. This monitoring includes blood tests to check kidney function (BUN/Creatinine) and clotting time (PT/INR).


Q: What is the safety class of Cefazol?

A: For use during pregnancy, Cefazolin is categorized by the FDA as Pregnancy Category B. This classification is used when animal studies have not shown a risk to the fetus, but there is a recognized absence of adequate and well-controlled studies in pregnant women.


Q: Does Cefazol affect my ability to drive or operate machinery?

A: Side effects such as dizziness, confusion, and seizures have been reported in official documents, especially at high doses or in patients with kidney problems. Due to the potential for these neurological effects, activities requiring mental alertness, such as driving or operating machinery, should be approached with awareness of this documented risk.


Q: Can Cefazol cause confusion or dizziness?

A: Yes, official documentation lists both dizziness and confusion among the reported adverse reactions associated with Cefazolin use. These side effects are related to the central nervous system and are more likely to be reported when drug levels in the blood are high.


Q: Is Cefazol used for infections of the bone?

A: Yes, the official indications for Cefazolin include the treatment of Bone and Joint Infections. It is specifically used for these infections when they are caused by susceptible strains of Staphylococcus aureus.


Q: Can I stop Cefazol if my symptoms improve quickly?

A: Regulatory guidance describes that Cefazolin treatment is intended to be used until the full prescribed course is completed, even if symptoms improve quickly. This approach supports the complete elimination of the infection and helps to reduce the risk of drug-resistant bacteria developing.

How should Cefazol be stored and disposed of?

How to Store and Dispose of Cefazolin

Cefazolin sterile powder must be stored at Controlled Room Temperature (20 C to 25 C). Storage must include protection from light and moisture, and the vial should be kept in a tightly closed container.

Stability and Handling

The powder must not be frozen. Once reconstituted, the solution's stability is limited and varies by formulation, often requiring use within hours at room temperature or up to 10 days under refrigeration (2 C to 8 C). Thawed premixed solutions must not be refrozen.

Disposal and Safety

Keep Cefazolin out of the sight and reach of children. Unused product and waste must be disposed of according to local regulations and should not be discarded via wastewater or household trash. Used needles and syringes must be placed in a puncture-proof sharps container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefazol found in:

A-Z Index: